Preclinical studies have shown that DPP-4 inhibitors can reduce inflammation [33], while Sun et al. [15] demonstrated that using the DPP-4 inhibitor, sitagliptin, improved glycemic control and insulin sensitivity in women with GDM. This evidence concerns the gene DPP4 and gestational diabetes.